GPER and EGFR cross-talk highlight aldosterone- and MR antagonist-induced NO production in cultured endothelial cells

Submitted by Anonymous on

IntroductionAldosterone induces rapid, non-genomic vasodilation of the rat mesenteric vasculature, and mineralocorticoid receptor (MR) antagonists are widely 1 Introduction Aldosterone, the principal mineralocorticoid hormone, plays critical roles in cardiovascular homeostasis beyond its classical genomic effects on renal sodium retention (Gomez-Sanchez...

AstraZeneca completes global license agreement for oral EGFR inhibitor ZEGFROVY® (sunvozertinib) for lung cancer

Submitted by Anonymous on

AstraZeneca today announced the successful completion of the previously announced exclusive license agreement with Dizal Pharmaceutical Co., Ltd for ZEGFROVY® (sunvozertinib), an oral irreversible epidermal growth factor receptor (EGFR) inhibitor for patients with lung cancer. Through this agreement, AstraZeneca has...

BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer

Submitted by Anonymous on

SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced that updated data...

AstraZeneca completes global license agreement for oral EGFR inhibitor ZEGFROVY (sunvozertinib) for lung cancer

Submitted by Anonymous on

AstraZeneca today announced the successful completion of the previously announced exclusive license agreement with Dizal Pharmaceutical Co., Ltd for ZEGFROVY (sunvozertinib), an oral irreversible epidermal growth factor receptor (EGFR) inhibitor for patients with lung cancer. Through this agreement, AstraZeneca has...

AstraZeneca completes global license agreement for oral EGFR inhibitor ZEGFROVY® (sunvozertinib) for lung cancer

Submitted by Anonymous on

WILMINGTON, Del., September 01, 2026--AstraZeneca today announced the successful completion of the previously announced exclusive license agreement with Dizal Pharmaceutical Co., Ltd for ZEGFROVY® (sunvozertinib), an oral irreversible epidermal growth factor receptor (EGFR) inhibitor for patients with lung cancer. Through...

Savolitinib Plus Osimertinib Improves First-Line PFS in MET-Overexpressing EGFR-Mutated NSCLC

Submitted by Anonymous on

Savolitinib Plus Osimertinib Improves First-Line PFS in MET-Overexpressing EGFR-Mutated NSCLC Savolitinib (Orpathys) plus osimertinib (Tagrisso) produced a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared with osimertinib alone in treatment-naive patients with EGFR-mutated, MET-overexpressing,. .1 The benefit...

HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit Of ORPATHYS® Plus TAGRISSO® In Treatment-Naïve Patients With MET-Overexpressing EGFR-mutated Lung Cancer In China

Submitted by Anonymous on

KIDieser Beitrag wurde mit Unterstützung künstlicher Intelligenz (KI) erstellt. TL;DR HUTCHMED has reported that its SANOVO trial demonstrated a significant improvement in progression-free survival for patients with MET-overexpressing EGFR-mutated lung cancer using ORPATHYS® combined with TAGRISSO®. The results are promising...

HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit of ORPATHYS® Plus TAGRISSO® in Treatment-Naïve Patients with MET-Overexpressing EGFR-mutated Lung Cancer...

Submitted by Anonymous on

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED“) (Nasdaq/AIM: HCM; HKEX: 13) today announces positive high-level results from the SANOVO China Phase III trial in treatment-naïve patients with locally advanced or metastatic...

Subscribe to Newsfeed